ENTA Enanta Pharmaceuticals Inc.
Health Care, filed as ENANTA PHARMACEUTICALS INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab
In 2026 Q3 Farallon Capital Management trimmed Enanta Pharmaceuticals.
Who owns this now
Largest portfolio weights among holders, up to 14.2% (Michael Krensavage, Krensavage Asset Management). Not free-float ownership.
Who owns ENTA
Sorted by value, long equity only, as of 2026 Q3.
| History | |||||
|---|---|---|---|---|---|
| Michael Krensavage, Krensavage Asset Management | Hold | 2,866,138 | $38M | History | |
| Farallon Capital Management | Reduce −60.7% | 950,000 | $13M | History | |
| James Silverman, Opaleye Management | Hold | 125,000 | $1.6M | History |
Insider trades
Open-market buys and sales by ENTA's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- None no planned (10b5-1) sales
No open-market buys or sales on file.
Also filed in the last 12 months, not counted as buying or selling: 14 stock grants, 13 share withholdings for taxes, and 9 sales to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 10-K | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 8-K | 5.02,7.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| DEF 14A | Filing Doc |
No filings match this filter.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total current assets | $422.79M | $299.85M | $204.34M | $205.99M |
| Total non-current assets * | $39.48M | $76.8M | $76.4M | $69.58M |
| Total assets | $462.28M | $376.65M | $280.73M | $275.58M |
| Total current liabilities | $62.79M | $57.54M | $48.56M | $54.46M |
| Total non-current liabilities * | $182.75M | $190.3M | $167.46M | $140.92M |
| Total equity | $216.74M | $128.81M | $64.72M | $80.2M |
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon